Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
$1.21
+0.8%
$1.29
$2.35
$11.55
$36M-0.39486,688 shs588,809 shs
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$15.68
-1.4%
$13.41
$9.83
$17.75
$147.14M0.917,778 shs26,588 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$11.90
+6.4%
$14.31
$5.22
$27.38
$149.29M0.41138,223 shs371,673 shs
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$3.00
+0.3%
$3.06
$1.45
$19.50
$99.26M1.27457,748 shs1.81 million shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
-5.51%-5.51%+2.56%-36.84%-88.24%
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
+1.27%+4.35%+50.50%+2.19%+8.71%
LifeVantage Co. stock logo
LFVN
LifeVantage
-6.83%-9.62%-21.16%-41.13%+76.34%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-8.52%-24.35%+66.09%-45.15%-77.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
4.1847 of 5 stars
3.73.00.00.02.53.33.1
LifeVantage Co. stock logo
LFVN
LifeVantage
4.163 of 5 stars
3.51.01.72.72.72.51.3
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
2.4785 of 5 stars
3.61.00.00.02.02.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
0.00
N/AN/AN/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
3.33
Buy$20.5030.74% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50156.41% Upside
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
3.17
Buy$22.20640.00% Upside

Current Analyst Ratings Breakdown

Latest ELYM, LFVN, LXEO, and FTLF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/8/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $22.00
4/8/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
3/26/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
3/25/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$24.00 ➝ $20.00
3/25/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
3/24/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $18.00
3/17/2025
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/A$3.90 per shareN/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$64.47M2.28$0.82 per share19.05$3.04 per share5.16
LifeVantage Co. stock logo
LFVN
LifeVantage
$212.15M0.70$0.63 per share19.03$2.38 per share5.00
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$650K153.22N/AN/A$4.26 per share0.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
-$35.12M-$0.53N/AN/AN/A-47.03%-45.97%N/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$5.30M$0.8418.5614.25N/A13.38%28.03%15.13%N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.5621.24N/A3.46%34.29%15.04%N/A
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$66.39M-$3.08N/AN/AN/AN/A-57.66%-48.18%5/8/2025 (Estimated)

Latest ELYM, LFVN, LXEO, and FTLF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.80N/AN/AN/AN/AN/A
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/27/2025Q4 2024
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$0.22$0.21-$0.01N/AN/AN/A
3/24/2025Q4 2024
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.87-$0.78+$0.09-$0.78N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/AN/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.161.35%N/A28.57%2 Years
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/AN/AN/AN/AN/A

Latest ELYM, LFVN, LXEO, and FTLF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/A
60.41
60.41
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
0.28
1.50
0.64
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
0.01
5.95
5.95

Institutional Ownership

CompanyInstitutional Ownership
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
69.76%
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
2.32%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
60.67%

Insider Ownership

CompanyInsider Ownership
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
4.70%
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
61.30%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
929.75 million28.35 millionNot Optionable
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
209.38 million3.56 millionNot Optionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.55 million9.96 millionOptionable
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
5833.20 million31.58 millionNot Optionable

Recent News About These Companies

Lexeo Therapeutics price target lowered to $22 from $25 at Chardan

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eliem Therapeutics stock logo

Eliem Therapeutics NASDAQ:ELYM

$1.21 +0.01 (+0.83%)
As of 05/7/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

FitLife Brands stock logo

FitLife Brands NASDAQ:FTLF

$15.68 -0.23 (-1.45%)
Closing price 03:59 PM Eastern
Extended Trading
$15.67 -0.01 (-0.06%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$11.90 +0.72 (+6.40%)
Closing price 03:59 PM Eastern
Extended Trading
$11.88 -0.02 (-0.17%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Lexeo Therapeutics stock logo

Lexeo Therapeutics NASDAQ:LXEO

$3.00 +0.01 (+0.33%)
Closing price 04:00 PM Eastern
Extended Trading
$3.18 +0.18 (+6.00%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.